Voyageur Pharmaceuticals Ltd. announced the formalization of a pivotal sales and distribution alliance with an internationally recognized pharmaceutical distribution company in Central America. This landmark agreement marks a significant milestone in Voyageur's journey, signaling its entry into the global market. This strategic partnership is a testament to Voyageur's unwavering commitment to excellence and innovation.

It grants the distributor exclusive rights within their designated territory, acknowledging their key role in securing regulatory licensing for Voyageur's suite of five barium contrast products. Given the sensitivity and competitive nature of the barium contrast market, Voyageur remains steadfast in maintaining strict confidentiality regarding client information, pricing, and sales volumes. Anticipating a pivotal launch in the first half of 2024, Voyageur is poised to unveil its comprehensive suite of five Health Canada licensed barium contrast products.

These innovative product solutions play a vital role in diagnosing diseases, disorders, and abnormalities throughout the digestive system, and are seamlessly integrated with X-ray and computed tomography (CT scan) procedures. The Frances Creek barium sulfate project holds significant potential, underscored by a Preliminary Economic Assessment (PEA) valuing it at an NPV of $344 million and projecting $839 million of pre-tax revenue over the next decade. Importantly, Voyageur stands out as one of the few providers of commercial natural pharmaceutical-grade barium sulfate on a global scale.

Currently importing synthetic man-made barium sulfate to meet market demands, Voyageur anticipates a substantial reduction in barium costs upon the successful production of Frances Creek barium sulfate. Looking ahead, Voyageur remains committed to revolutionize medical imaging solutions, generating substantial value for its shareholders. The Company appreciates continued support as it embarks on this transformative phase of growth and market expansion.